Personalized Treatment of Urogenital Cancers Depends on the Microbiome

• Status: Recruiting
• Trial end date: 2027-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zealand University Hospital
• Treatments: Tigecycline

Criteria

Inclusion Criteria:

• Biopsy verified diagnosis of urological cancer, localized disease

Exclusion Criteria:

• Hospitalization within three months of surgery

• Antibiotics within three months of surgery

• Infectious disease, including UTI's within three months of surgery

• History of cancers of the genitourinary tract

• Diabetes